VIMIAN logo

Vimian Group AB (publ) Stock Price

OM:VIMIAN Community·SEK 15.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

VIMIAN Share Price Performance

SEK 28.56
-15.94 (-35.82%)
44.7% undervalued intrinsic discount
SEK 51.65
Fair Value
SEK 28.56
-15.94 (-35.82%)
44.5% undervalued intrinsic discount
SEK 51.44
Fair Value
Price SEK 28.56
AnalystHighTarget SEK 51.44
AnalystConsensusTarget SEK 38.90
AnalystLowTarget SEK 37.20

VIMIAN Community Narratives

AnalystHighTarget·
Fair Value SEK 51.65 44.7% undervalued intrinsic discount

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value SEK 38.9 26.6% undervalued intrinsic discount

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value SEK 37.32 23.5% undervalued intrinsic discount

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent VIMIAN News & Updates

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Vimian Group AB (publ) Key Details

€404.3m

Revenue

€126.4m

Cost of Revenue

€277.9m

Gross Profit

€255.1m

Other Expenses

€22.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 22, 2025
Earnings per share (EPS)
0.043
Gross Margin
68.74%
Net Profit Margin
5.64%
Debt/Equity Ratio
40.1%

Vimian Group AB (publ) Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Reasonable growth potential with proven track record.

0 Risks
4 Rewards

About VIMIAN

Founded
2020
Employees
1200
CEO
Carl-Johan Boudrie
WebsiteView website
vimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Swedish Market Performance

  • 7 Days: -0.5%
  • 3 Months: 2.9%
  • 1 Year: -0.6%
  • Year to Date: 2.3%
Over the last 7 days, the market has dropped 1.3%, driven by a decline of 1.7% in the Industrials sector. On the other hand, the Real Estate has risen by 3.2%. Although the market performance has been flat over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›